Catabasis is enrolling boys ages 4 to 7 (up to 8th birthday), any mutation type, who have not been on steroids for at least the past six months.
What is Edasalonexent?
Edasalonexent (CAT-1004 is being developed as a potential foundational disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. It is an investigational oral small molecule. Edasalonexent inhibits NF-kB, a protein that is activated by DMD and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasalonexent was designed as a stand-alone therapy and may also enhance the efficacy of dystrophin targeted therapies.
Potential bone health benefits of edasalonexent
Why is bone health so important in Duchenne?
Boys with Duchenne are at an increased risk of bone fractures and should be monitored yearly to check for fractures. Early detection is critical. Strong bones are essential to help boys grow taller! Some therapies used to treat Duchenne have an additional negative impact on bone health and can increase the frequency of long bone and spine fractures.
Catabasis believes that edasalonexent has the potential to benefit bone health, which is why they are studying it in their Phase 3 PolarisDMD trial. Because edasalonexent is an NF-kB inhibitor, it has the potential to reduce inflammation and promote muscle regeneration, and that can strengthen bones. Catabasis will perform x-rays and body scans at the beginning and end of the study to check on bone health!
PolarisDMD in Canada
If you’d like to learn more, contact Catabasis at DMDtrials@catabasis.com. Catabasis is also sharing updates on edasalonexent @CatabasisPharma on Facebook, Twitter and Instagram if you are interested in the latest updates. Get the story behind the PolarisDMD experience! – Here –
Ontario
- Children’s Hospital-London Health Sciences Centre, this site is expected to be enrolling soon
- Principal Investigator: Craig Campbell
- Children’s Hospital Eastern Ontario, this site is expected to be enrolling soon
- Principal Investigator: Hugh McMillian
Alberta
- Alberta Children’s Hospital is actively recruiting
- Principal Investigator: Jean Mah
Quebec
- Sainte-Justine Hospital, this site is expected to be enrolling soon
- Principal Investigator: Cam-Tu Nguyen
Sources and for more information
More about Catabasis: www.catabasis.com
Portrait of Duchenne – edasalonexent cat-1004 – La Force DMD
More information about the Polaris DMD trial: Catabasis – Polaris DMD
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (PolarisDMD)
